NeuroPace, Inc.
NPCE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.42 | -0.44 | -0.88 | 3.03 |
| FCF Yield | -0.58% | -0.62% | -1.94% | -1.44% |
| EV / EBITDA | -159.15 | -67.83 | -108.97 | -151.38 |
| Quality | ||||
| ROIC | -2.90% | -7.50% | -5.28% | -4.49% |
| Gross Margin | 77.39% | 77.09% | 76.99% | 75.41% |
| Cash Conversion Ratio | 0.56 | 0.24 | 1.14 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.37% | 17.26% | 20.14% | 20.63% |
| Free Cash Flow Growth | 12.42% | 70.02% | -55.48% | -165.13% |
| Safety | ||||
| Net Debt / EBITDA | -20.51 | -7.96 | -11.61 | -22.98 |
| Interest Coverage | -2.66 | -3.31 | -2.39 | -1.67 |
| Efficiency | ||||
| Inventory Turnover | 0.34 | 0.33 | 0.38 | 0.39 |
| Cash Conversion Cycle | 246.21 | 246.05 | 227.26 | 231.68 |